Brenton Taylor Sells 2,869 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Brenton Taylor sold 2,869 shares of Sight Sciences stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $10,615.30. Following the completion of the sale, the executive vice president directly owned 267,807 shares in the company, valued at approximately $990,885.90. The trade was a 1.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Brenton Taylor also recently made the following trade(s):

• On Tuesday, January 6th, Brenton Taylor sold 619 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $4,630.12.

Sight Sciences Stock Performance

SGHT stock opened at $3.52 on Friday. The firm has a fifty day moving average price of $4.82 and a 200 day moving average price of $5.74. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $9.24. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. The firm has a market cap of $190.12 million, a PE ratio of -4.69 and a beta of 2.50.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. The company had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.35 million. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. Sell-side analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SGHT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. UBS Group lowered their price target on Sight Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Piper Sandler set a $9.00 price objective on shares of Sight Sciences in a research note on Monday, January 5th. Finally, Cantor Fitzgerald set a $8.00 price target on shares of Sight Sciences in a research report on Monday, March 2nd. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sight Sciences currently has a consensus rating of “Hold” and an average price target of $8.31.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SGHT. Integral Health Asset Management LLC purchased a new stake in shares of Sight Sciences during the 4th quarter worth $3,370,000. Americana Partners LLC grew its stake in Sight Sciences by 42.4% in the third quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after purchasing an additional 365,901 shares during the last quarter. Invesco Ltd. purchased a new position in Sight Sciences in the fourth quarter valued at about $2,791,000. Walleye Capital LLC bought a new position in Sight Sciences in the fourth quarter worth about $2,332,000. Finally, Informed Momentum Co LLC bought a new position in Sight Sciences in the fourth quarter worth about $1,299,000. 55.51% of the stock is owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.